par Awada, Ahmad ;Gil, Thierry ;de Valeriola, Dominique ;Dubuisson, Michel ;Lalami, Yassine ;Moerman, C;Palmer, P;De Porre, Peter;Zhang, Steven;Piccart-Gebhart, Martine ; [et al.]
Référence Current medical research and opinion, 23, 5, page (991-1003)
Publication Publié, 2007-05
Article révisé par les pairs
Titre:
  • A phase I Clinical and Pharmacokinetic study of Tipifarnib in combination with Docetaxel in patients with advanced solid malignancies.
Auteur:Awada, Ahmad; Gil, Thierry; de Valeriola, Dominique; Dubuisson, Michel; Lalami, Yassine; Moerman, C; Palmer, P; De Porre, Peter; Zhang, Steven; Piccart-Gebhart, Martine; et al.
Informations sur la publication:Current medical research and opinion, 23, 5, page (991-1003)
Statut de publication:Publié, 2007-05
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Docetaxel
Farnesyltransferase inhibitor
Pharmacokinetics
Phase I
Solid cancer
Tipifarnib
MeSH keywords:Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Dose-Response Relationship, Drug
Drug Administration Routes
Drug Administration Schedule
Drug Interactions
Female
Humans
Immune System -- drug effects
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms -- drug therapy
Neoplasms -- pathology
Quinolones -- administration & dosage
Quinolones -- adverse effects
Quinolones -- pharmacokinetics
Taxoids -- administration & dosage
Taxoids -- adverse effects
Taxoids -- pharmacokinetics
Treatment Outcome
Note générale:Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0300-7995
info:doi/10.1185/030079907X178810
info:scp/34249022680
info:pmid/17519066

Documents en relation

DI-fusion